Literature DB >> 29092973

Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy.

Yoh Arita1, Takatsugu Segawa1, Shohei Yamamoto1, Shinji Hasegawa1.   

Abstract

Septic shock is a life-threatening condition that occurs when the blood pressure drops to a low level after an infection. Atrial fibrillation (AF) is the most common arrhythmia to complicate its course. Beta (β)-blockers are often administrated to manage supraventricular tachyarrhythmias observed in patients presenting with sepsis. A 74-year-old woman presenting with sepsis demonstrated AF tachycardia characterised by severe hypotension. She was refractory to conventional therapy including verapamil and digoxin; therefore, treatment using landiolol (an ultrashort-acting β-blocker) was initiated. Her clinical course was followed over 48 hours, and she showed a significant improvement in her heart rate and blood pressure without any adverse effect. Landiolol can rapidly control the accelerated heart rate associated with AF in critically decompensated patients presenting with septic shock. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  adult intensive care; arrhythmias; cardiovascular system

Mesh:

Substances:

Year:  2017        PMID: 29092973      PMCID: PMC5695360          DOI: 10.1136/bcr-2017-222268

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Practice Patterns and Outcomes of Treatments for Atrial Fibrillation During Sepsis: A Propensity-Matched Cohort Study.

Authors:  Allan J Walkey; Stephen R Evans; Michael R Winter; Emelia J Benjamin
Journal:  Chest       Date:  2016-01-06       Impact factor: 9.410

Review 2.  Severe sepsis and septic shock.

Authors:  Derek C Angus; Tom van der Poll
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

3.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Authors:  Mervyn Singer; Clifford S Deutschman; Christopher Warren Seymour; Manu Shankar-Hari; Djillali Annane; Michael Bauer; Rinaldo Bellomo; Gordon R Bernard; Jean-Daniel Chiche; Craig M Coopersmith; Richard S Hotchkiss; Mitchell M Levy; John C Marshall; Greg S Martin; Steven M Opal; Gordon D Rubenfeld; Tom van der Poll; Jean-Louis Vincent; Derek C Angus
Journal:  JAMA       Date:  2016-02-23       Impact factor: 56.272

4.  Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis.

Authors:  Allan J Walkey; Renda Soylemez Wiener; Joanna M Ghobrial; Lesley H Curtis; Emelia J Benjamin
Journal:  JAMA       Date:  2011-11-13       Impact factor: 56.272

Review 5.  Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.

Authors:  P Turlapaty; A Laddu; V S Murthy; B Singh; R Lee
Journal:  Am Heart J       Date:  1987-10       Impact factor: 4.749

6.  Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.

Authors:  Andrea Morelli; Christian Ertmer; Martin Westphal; Sebastian Rehberg; Tim Kampmeier; Sandra Ligges; Alessandra Orecchioni; Annalia D'Egidio; Fiorella D'Ippoliti; Cristina Raffone; Mario Venditti; Fabio Guarracino; Massimo Girardis; Luigi Tritapepe; Paolo Pietropaoli; Alexander Mebazaa; Mervyn Singer
Journal:  JAMA       Date:  2013-10-23       Impact factor: 56.272

Review 7.  Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

8.  Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).

Authors:  Ryozo Nagai; Koichiro Kinugawa; Hiroshi Inoue; Hirotsugu Atarashi; Yoshihiko Seino; Takeshi Yamashita; Wataru Shimizu; Takeshi Aiba; Masafumi Kitakaze; Atsuhiro Sakamoto; Takanori Ikeda; Yasushi Imai; Takashi Daimon; Katsuhiro Fujino; Tetsuji Nagano; Tatsuaki Okamura; Masatsugu Hori
Journal:  Circ J       Date:  2013-03-15       Impact factor: 2.993

9.  Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.

Authors:  Masaki Okajima; Masayuki Takamura; Takumi Taniguchi
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 10.  Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review.

Authors:  Sanne Kuipers; Peter M C Klein Klouwenberg; Olaf L Cremer
Journal:  Crit Care       Date:  2014-12-15       Impact factor: 9.097

View more
  4 in total

1.  Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study.

Authors:  Naoyuki Matsuda; Osamu Nishida; Takumi Taniguchi; Masaki Okajima; Hiroshi Morimatsu; Hiroshi Ogura; Yoshitsugu Yamada; Tetsuji Nagano; Akira Ichikawa; Yasuyuki Kakihana
Journal:  EClinicalMedicine       Date:  2020-10-13

2.  The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature.

Authors:  Sofia Bezati; Maria Velliou; Eftihia Polyzogopoulou; Antonios Boultadakis; John Parissis
Journal:  Eur Heart J Suppl       Date:  2022-06-13       Impact factor: 1.624

3.  Bisoprolol Transdermal Patch Is Effective for the Treatment of AF Tachycardia.

Authors:  Yoh Arita; Hajime Saeki; Miwa Miyoshi; Shinji Hasegawa
Journal:  Case Rep Cardiol       Date:  2018-05-21

4.  Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial.

Authors:  Ranjit Lall; Dipesh Mistry; Emma Skilton; Nafisa Boota; Scott Regan; Julian Bion; Simon Gates; Anthony C Gordon; Janet Lord; Daniel Francis McAuley; Gavin Perkins; Mervyn Singer; Duncan Young; Tony Whitehouse
Journal:  BMJ Open       Date:  2021-02-16       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.